{"entity":{"id":"nct07366840","kind":"trial","name":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure","aka":[],"tldr":"A phase 2/3 trial of Disitamab vedotin, Gemcitabine, Capecitabine, Trastuzumab and Inetetamab in HER2-positive breast cancer and Breast cancer, run by Fudan University, not yet recruiting.","summary":"RC48 Combined With Chemotherapy in HER2-Positive Advanced Breast Cancer Patients With Prior TOP1i-ADC Failure is a phase 2/3 interventional study registered as NCT07366840 by Fudan University, with 268 participants planned, started 2026-01-16 and due to reach its primary completion in 2028-01-16. Interventions recorded: Disitamab Vedotin, Gemcitabine, Capecitabine, Trastuzumab, Inetetamab. Conditions recorded: HER2-positive Breast Cancer, Metastatic Breast Cancer.\n\nLinked to the drug Inetetamab because the registry names it among its interventions and HER2-positive breast cancer and Breast cancer among its conditions. Registry record only: no result has been read by an editor.","status":"planned","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT07366840","url":"https://clinicaltrials.gov/study/NCT07366840"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-her2-positive","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["disitamab-vedotin","gemcitabine","capecitabine","trastuzumab","inetetamab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07366840","phase":"2/3","setting":"A Phase 3, Randomized Advanced Breast Cancer Study Investigating RC48 Combined With Chemotherapy Versus Guideline-recommended Trastuzumab/Inetetamab Plus Chemotherapy in HER2-Positive Patients With Prior TOP1i-ADC Failure","sponsor":"Fudan University","enrolled":268,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07366840/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"disitamab-vedotin","kind":"drug","name":"Disitamab vedotin","route":"/drugs/disitamab-vedotin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"inetetamab","kind":"drug","name":"Inetetamab","route":"/drugs/inetetamab/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}]}}